Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
A beta version of a prescription digital therapeutic significantly reduced experiential negative symptoms in patients with schizophrenia, according to a poster presentation at Psych Congress.
A beta version of a prescription digital therapeutic significantly reduced experiential negative symptoms in patients with schizophrenia, according to a poster presentation at Psych Congress.
An online pain management program reduced anxiety and depressive symptoms in adults with chronic pain, according to study results published online ahead of print in Pain Medicine.
An online pain management program reduced anxiety and depressive symptoms in adults with chronic pain, according to study results published online ahead of print in Pain Medicine.
The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...
The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...
Four weeks of daily, home-based transcranial direct current stimulation (tDCS) improved attention in adults with ADHD not taking stimulant medication, according to a small sham-controlled trial.
Four weeks of daily, home-based transcranial direct current stimulation (tDCS) improved attention in adults with ADHD not taking stimulant medication, according to a small sham-controlled trial.
The FDA recently granted Abbott a breakthrough device designation to investigate the use of its deep brain stimulation system for patients with treatment-resistant depression, a form of major depressive disorder.
The FDA recently granted Abbott a breakthrough device designation to investigate the use of its deep brain stimulation system for patients with treatment-resistant depression, a form of major depressive disorder.
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
